Industry "vulnerability" to private litigation is concern of FDA's Office of Enforcement.
INDUSTRY "VULNERABILITY" TO PRIVATE LITIGATION IS CONCERN TO FDA, Enforcement Office Director Daniel Michels told a Regulatory Affairs Professionals Society meeting Feb. 28. Michels reported that his office received "in excess of 240 requests for testimony of FDA employees" in 1994 in "an increasing number of private suits being brought against your firms, between firms as well as corporate stockholder suits."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth